Purpose

This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of the prostate within 270 days prior to registration - Unfavorable intermediate risk prostate cancer, defined as having ALL the following bulleted criteria: - Has at least one intermediate risk factor (IRF): - PSA 10-20 ng/mL - Clinical stage T2b-c (digital rectal examination [DRE] and/or imaging) by American Joint Committee on Cancer (AJCC) 8th edition - Gleason score 7 (Gleason 3+4 or 4+3 [ International Society of Urological Pathology (ISUP) Grade Group 2-3]) - Has ONE or more of the following 'unfavorable' intermediate-risk designators: - > 1 immature reticulocyte fraction (IRF) - Gleason 4+3=7 (ISUP Grade Group 3) - >= 50% of biopsy cores positive - Biopsies may include 'sextant' sampling of right/left regions of the prostate, often labeled base, mid-gland and apex. All such 'sextant' biopsy cores should be counted. Men may also undergo 'targeted' sampling of prostate lesions (guided by MRI, ultrasound or other approaches). A targeted lesion that is biopsied more than once and demonstrates cancer (regardless of number of targeted cores involved) should count as a single additional positive core sampled and positive. In cases of uncertainty, count the biopsy sampling as sextant core(s) - Absence of high-risk features - Appropriate stage for study entry based on the following diagnostic workup: - History/physical examination within 120 days prior to registration; - Negative bone imaging (M0) within 120 days prior to registration; Note: Tc-99m bone scan or sodium fluoride (NaF) positron emission tomography (PET) are allowed. Equivocal bone scan findings are allowed if plain films X-ray, computed tomography (CT) or magnetic resonance imaging (MRI) are negative for metastasis at the concerned site(s). While a negative fluciclovine, choline, or prostate specific membrane antigen (PSMA) PET may be counted as acceptable substitute for bone imaging, any suspicious findings must be confirmed and correlated with conventional imaging (Tc-99m bone scan, NaF PET, CT, X-ray, or MRI) to determine eligibility based on the latter modalities (e.g. M0 based on conventional imaging modalities) - Clinically negative lymph nodes (N0) as established by conventional imaging (pelvic +/- abdominal CT or MR), within 120 days prior to registration. Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are =< 1.0 cm in short axis and/or if biopsy is negative. Note: While a negative fluciclovine, choline, or prostate specific membrane antigen (PSMA) PET may be counted as acceptable substitute for pelvic imaging, any suspicious findings must be confirmed by conventional imaging (CT, MRI or biopsy). If the findings do not meet pathological criteria based on the latter modalities (e.g. node =< 10 mm in short axis, negative biopsy), the patient will still be eligible - Age >= 18 - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 120 days prior to registration - Non-castrate testosterone level (> 50 ng/dL) within 120 days prior to registration - Absolute neutrophil >= 1,000 cells/mm^3 (within 120 days prior to registration) - Hemoglobin >= 8.0 g/dL, independent of transfusion and/or growth factors (within 120 days prior to registration) - Platelet count >= 100,000 cells/mm^3 independent of transfusion and/or growth factors (within 120 days prior to registration) - Creatinine clearance (CrCl) >= 30 mL/min estimated by Cockcroft-Gault equation (within 120 days prior to registration) - For African American patients specifically whose renal function is not considered adequate by the formula above, an alternative formula that takes race into account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) should be used for calculating the related estimated glomerular filtration rate (GFR) with a correction factor for African American race creatinine clearance for trial eligibility, where GFR >= 30 mL/min/1.73m^2 will be considered adequate - Total bilirubin: 1.5 =< institutional upper limit of normal (ULN) (within 120 days prior to registration) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is less than or equal to 1.5 x ULN, subject is eligible) - Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]): =< 2.5 x institutional ULN (within 120 days prior to registration) - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial; Note: HIV testing is not required for eligibility for this protocol - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. - Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B) - For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria

  • Previous radical surgery (prostatectomy) or any form of curative-intent ablation whether focal or whole-gland (e.g., cryosurgery, high intensity focused ultrasound [HIFU], laser thermal ablation, etc.) for prostate cancer - Definitive clinical or radiologic evidence of metastatic disease (M1) - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years. History of or current diagnosis of hematologic malignancy is not allowed - Prior radiotherapy to the prostate/pelvis region that would result in overlap of radiation therapy fields - Previous bilateral orchiectomy - Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate). ADT started prior to study registration is not allowed - Prior use of 5-alpha-reductase inhibitors is allowed, however, it must be stopped prior to enrollment on the study with at least a 30 day washout period before baseline study PSA measure and registration - Active testosterone replacement therapy; any replacement therapy must be stopped at least 30 days prior to registration - Severe, active co-morbidity defined as follows: - Current severe or unstable angina; - New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification) - History of any condition that in the opinion of the investigator, would preclude participation in this study - Inability to swallow oral pills - High risk features, which includes any of the following: - Gleason 8-10 [ISUP Grade Group 4-5] - PSA > 20 - cT3-4 by digital exam OR gross extra-prostatic extension on imaging [indeterminate MRI evidence will not count and the patient will be eligible]

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm I (RT)
Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity.
  • Radiation: Radiation Therapy
    Undergo RT
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
Experimental
Arm II (RT, ADT)
Patients undergo RT as Arm I. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days.
  • Drug: Bicalutamide
    Anti-androgen
    Other names:
    • Casodex
    • Cosudex
    • ICI 176,334
    • ICI 176334
  • Drug: Buserelin
    GnRH agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Degarelix
    GnRH antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Flutamide
    Anti-androgen
    Other names:
    • 4'-Nitro-3'-trifluoromethylisobutyranilide
    • Apimid
    • Cebatrol
    • Chimax
    • Cytomid
    • Drogenil
    • Euflex
    • Eulexine
    • Flucinom
    • Flucinome
    • Flugerel
    • Fluken
    • Flulem
    • FLUT
    • Fluta-Gry
    • Flutabene
    • Flutacan
    • Flutamex
    • Flutamin
    • Flutan
    • Flutaplex
    • Fugerel
    • Grisetin
    • Niftolide
    • Oncosal
    • Profamid
    • Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-
    • Prostacur
    • Prostadirex
    • Prostica
    • Prostogenat
    • Sch 13521
    • Tafenil
    • Tecnoflut
    • Testotard
  • Drug: Goserelin
    GnRH agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    GnRH agonist
  • Drug: Leuprolide
    GnRH agonist
    Other names:
    • Leuprorelin
  • Radiation: Radiation Therapy
    Undergo RT
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Relugolix
    GnRH antagonist
    Other names:
    • N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea
    • Orgovyx
    • TAK 385
    • TAK-385
  • Drug: Triptorelin
    GnRH agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline
Experimental
Arm III (RT, ADT)
Patients receive treatment as in Arm II.
  • Drug: Bicalutamide
    Anti-androgen
    Other names:
    • Casodex
    • Cosudex
    • ICI 176,334
    • ICI 176334
  • Drug: Buserelin
    GnRH agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Degarelix
    GnRH antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Flutamide
    Anti-androgen
    Other names:
    • 4'-Nitro-3'-trifluoromethylisobutyranilide
    • Apimid
    • Cebatrol
    • Chimax
    • Cytomid
    • Drogenil
    • Euflex
    • Eulexine
    • Flucinom
    • Flucinome
    • Flugerel
    • Fluken
    • Flulem
    • FLUT
    • Fluta-Gry
    • Flutabene
    • Flutacan
    • Flutamex
    • Flutamin
    • Flutan
    • Flutaplex
    • Fugerel
    • Grisetin
    • Niftolide
    • Oncosal
    • Profamid
    • Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-
    • Prostacur
    • Prostadirex
    • Prostica
    • Prostogenat
    • Sch 13521
    • Tafenil
    • Tecnoflut
    • Testotard
  • Drug: Goserelin
    GnRH agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    GnRH agonist
  • Drug: Leuprolide
    GnRH agonist
    Other names:
    • Leuprorelin
  • Radiation: Radiation Therapy
    Undergo RT
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Relugolix
    GnRH antagonist
    Other names:
    • N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea
    • Orgovyx
    • TAK 385
    • TAK-385
  • Drug: Triptorelin
    GnRH agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline
Experimental
Arm IV (RT, ADT, darolutamide)
Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
  • Drug: Buserelin
    GnRH agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Darolutamide
    Anti-androgen
    Other names:
    • Antiandrogen ODM-201
    • BAY 1841788
    • BAY-1841788
    • BAY1841788
    • Nubeqa
    • ODM 201
    • ODM-201
  • Drug: Degarelix
    GnRH antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Goserelin
    GnRH agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    GnRH agonist
  • Drug: Leuprolide
    GnRH agonist
    Other names:
    • Leuprorelin
  • Radiation: Radiation Therapy
    Undergo RT
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Relugolix
    GnRH antagonist
    Other names:
    • N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea
    • Orgovyx
    • TAK 385
    • TAK-385
  • Drug: Triptorelin
    GnRH agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline

Recruiting Locations

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
Contact:
Site Public Contact
205-934-0220
tmyrick@uab.edu

Banner MD Anderson Cancer Center
Gilbert, Arizona 85234
Contact:
Site Public Contact
602-747-9738

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Site Public Contact
501-686-8274

Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California 95603
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California 93301
Contact:
Site Public Contact
661-323-4673

Tower Cancer Research Foundation
Beverly Hills, California 90211
Contact:
Site Public Contact
towercancerresearch@toweroncology.com

Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California 95682
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

City of Hope Corona
Corona, California 92879
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

City of Hope Comprehensive Cancer Center
Duarte, California 91010
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente Dublin
Dublin, California 94568
Contact:
Site Public Contact
877-642-4691

Kaiser Permanente-Fremont
Fremont, California 94538
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Washington Hospital
Fremont, California 94538
Contact:
Site Public Contact
510-745-6433

Kaiser Permanente-Fresno
Fresno, California 93720
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Marin General Hospital
Greenbrae, California 94904
Contact:
Site Public Contact
415-925-7325

City of Hope at Irvine Lennar
Irvine, California 92618
Contact:
Site Public Contact
877-467-3411

City of Hope Antelope Valley
Lancaster, California 93534
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Los Angeles General Medical Center
Los Angeles, California 90033
Contact:
Site Public Contact
323-865-0451
uscnorrisinfo@med.usc.edu

USC / Norris Comprehensive Cancer Center
Los Angeles, California 90033
Contact:
Site Public Contact
323-865-0451

Cedars Sinai Medical Center
Los Angeles, California 90048
Contact:
Site Public Contact
310-423-8965

Fremont - Rideout Cancer Center
Marysville, California 95901
Contact:
Site Public Contact
530-749-4400

Memorial Medical Center
Modesto, California 95355
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

Kaiser Permanente-Modesto
Modesto, California 95356
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Providence Queen of The Valley
Napa, California 94558
Contact:
Site Public Contact
707-521-3830

Kaiser Permanente-Oakland
Oakland, California 94611
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Saint Joseph Hospital - Orange
Orange, California 92868
Contact:
Site Public Contact
714-734-6220

Kaiser Permanente-Roseville
Roseville, California 95661
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California 95661
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

Kaiser Permanente Downtown Commons
Sacramento, California 95814
Contact:
Site Public Contact
877-642-4691
kpoct@kp.org

Sutter Medical Center Sacramento
Sacramento, California 95816
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
Contact:
Site Public Contact
916-734-3089

Kaiser Permanente-South Sacramento
Sacramento, California 95823
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-San Francisco
San Francisco, California 94115
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

UCSF Medical Center-Mission Bay
San Francisco, California 94158
Contact:
Site Public Contact
877-827-3222
cancertrials@ucsf.edu

Kaiser Permanente-Santa Teresa-San Jose
San Jose, California 95119
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente San Leandro
San Leandro, California 94577
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Ridley-Tree Cancer Center
Santa Barbara, California 93105
Contact:
Site Public Contact
research@ridleytreecc.org

Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California 95051
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Santa Rosa
Santa Rosa, California 95403
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

City of Hope South Pasadena
South Pasadena, California 91030
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente-South San Francisco
South San Francisco, California 94080
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Cedars-Sinai Cancer - Tarzana
Tarzana, California 91356
Contact:
Site Public Contact
818-981-3818

City of Hope South Bay
Torrance, California 90503
Contact:
Site Public Contact
877-467-3411

Torrance Memorial Physician Network - Cancer Care
Torrance, California 90505
Contact:
Site Public Contact
310-750-3300
courtney.steeneken@tmphysicians.com

Torrance Memorial Medical Center
Torrance, California 90509
Contact:
Site Public Contact
310-517-4665

Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California 96161
Contact:
Site Public Contact
530-582-6450

City of Hope Upland
Upland, California 91786
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente-Vallejo
Vallejo, California 94589
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Walnut Creek
Walnut Creek, California 94596
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

UCHealth University of Colorado Hospital
Aurora, Colorado 80045
Contact:
Site Public Contact
720-848-0650

Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado 80304
Contact:
Site Public Contact
303-777-2663
info@westernstatesncorp.org

UCHealth Memorial Hospital Central
Colorado Springs, Colorado 80909
Contact:
Site Public Contact
719-365-2406

Memorial Hospital North
Colorado Springs, Colorado 80920
Contact:
Site Public Contact
719-364-6700

Shaw Cancer Center
Edwards, Colorado 81632
Contact:
Site Public Contact
970-569-7429

Poudre Valley Hospital
Fort Collins, Colorado 80524
Contact:
Site Public Contact
970-297-6150

Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado 80528
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

North Colorado Medical Center
Greeley, Colorado 80631
Contact:
Site Public Contact
970-810-3046
BMDACCResearchCOMailbox@bannerhealth.com

UCHealth Greeley Hospital
Greeley, Colorado 80631
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado 80129
Contact:
Site Public Contact
720-848-0650

Medical Center of the Rockies
Loveland, Colorado 80538
Contact:
Site Public Contact
970-203-7083

McKee Medical Center
Loveland, Colorado 80539
Contact:
Site Public Contact
970-810-3046
BMDACCResearchCOMailbox@bannerhealth.com

Hartford HealthCare - Saint Vincent's Medical Center
Bridgeport, Connecticut 06606
Contact:
Site Public Contact
860-972-4700

Hartford Hospital
Hartford, Connecticut 06102
Contact:
Site Public Contact
860-545-5363

Midstate Medical Center
Meriden, Connecticut 06451
Contact:
Site Public Contact
866-662-5678

The Hospital of Central Connecticut
New Britain, Connecticut 06050
Contact:
Site Public Contact
860-224-5660

Norwalk Hospital
Norwalk, Connecticut 06856
Contact:
Site Public Contact
203-852-2996
jennifer.long@norwalkhealth.org

Beebe South Coastal Health Campus
Frankford, Delaware 19945
Contact:
Site Public Contact
302-291-6730
research@beebehealthcare.org

Helen F Graham Cancer Center
Newark, Delaware 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Medical Oncology Hematology Consultants PA
Newark, Delaware 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Beebe Health Campus
Rehoboth Beach, Delaware 19971
Contact:
Site Public Contact
302-291-6730
research@beebehealthcare.org

University of Florida Health Science Center - Gainesville
Gainesville, Florida 32610
Contact:
Site Public Contact
352-273-8010
cancer-center@ufl.edu

GenesisCare USA - Plantation
Plantation, Florida 33324
Contact:
Site Public Contact
941-833-5700
Rudi.Ross@usa.genesiscare.com

Cleveland Clinic-Weston
Weston, Florida 33331
Contact:
Site Public Contact
954-659-5705
CancerAnswer@ccf.org

Grady Health System
Atlanta, Georgia 30303
Contact:
Site Public Contact
404-489-9164

Emory Proton Therapy Center
Atlanta, Georgia 30308
Contact:
Site Public Contact
404-251-2854
allyson.anderson@emory.edu

Emory University Hospital Midtown
Atlanta, Georgia 30308
Contact:
Site Public Contact
888-946-7447

Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Site Public Contact
404-778-1868

Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
Contact:
Site Public Contact
404-851-7115

Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia 30501
Contact:
Site Public Contact
770-219-8800
cancerpatient.navigator@nghs.com

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia 31405
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Saint Luke's Cancer Institute - Boise
Boise, Idaho 83712
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho 83619
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Meridian
Meridian, Idaho 83642
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Nampa
Nampa, Idaho 83686
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho 83301
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Canton
Canton, Illinois 61520
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Carthage
Carthage, Illinois 62321
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern University
Chicago, Illinois 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

Rush University Medical Center
Chicago, Illinois 60612
Contact:
Site Public Contact
312-942-5498
clinical_trials@rush.edu

University of Illinois
Chicago, Illinois 60612
Contact:
Site Public Contact
312-355-3046

Carle at The Riverfront
Danville, Illinois 61832
Contact:
Site Public Contact
800-446-5532
Research@Carle.com

Decatur Memorial Hospital
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois 60115
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Crossroads Cancer Center
Effingham, Illinois 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Elmhurst Memorial Hospital
Elmhurst, Illinois 60126
Contact:
Site Public Contact
630-758-5460
Jrohde@emhc.org

Illinois CancerCare-Eureka
Eureka, Illinois 61530
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Cancer Center Delnor
Geneva, Illinois 60134
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

Illinois CancerCare-Macomb
Macomb, Illinois 61455
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Loyola University Medical Center
Maywood, Illinois 60153
Contact:
Site Public Contact
708-226-4357

Edward Hospital/Cancer Center
Naperville, Illinois 60540
Contact:
Site Public Contact
630-646-6075

Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Pekin
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peoria
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Methodist Medical Center of Illinois
Peoria, Illinois 61636
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peru
Peru, Illinois 61354
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Princeton
Princeton, Illinois 61356
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

SwedishAmerican Regional Cancer Center/ACT
Rockford, Illinois 61114
Contact:
Site Public Contact
779-696-9378
lkline@uwhealth.org

Memorial Hospital East
Shiloh, Illinois 62269
Contact:
Site Public Contact
314-747-9912
dschwab@wustl.edu

Memorial Medical Center
Springfield, Illinois 62781
Contact:
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Carle Cancer Center
Urbana, Illinois 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois 60555
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare - Washington
Washington, Illinois 61571
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Saint Luke's Hospital
Cedar Rapids, Iowa 52402
Contact:
Site Public Contact
319-368-5514
Rachel.varner@unitypoint.org

Iowa Methodist Medical Center
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-6727

University of Kansas Cancer Center
Kansas City, Kansas 66160
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Olathe Health Cancer Center
Olathe, Kansas 66061
Contact:
Site Public Contact
913-355-8000
Jeni.wakefield@olathehealth.org

University of Kansas Cancer Center-Overland Park
Overland Park, Kansas 66210
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas 66211
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Salina Regional Health Center
Salina, Kansas 67401
Contact:
Site Public Contact
785-452-7038
mleepers@srhc.com

Cotton O'Neil Cancer Center / Stormont Vail Health
Topeka, Kansas 66606
Contact:
Site Public Contact
785-270-4939

University of Kansas Health System Saint Francis Campus
Topeka, Kansas 66606
Contact:
Site Public Contact
785-295-8000

University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Ascension Via Christi Hospitals Wichita
Wichita, Kansas 67214
Contact:
Site Public Contact
316-291-4774
research@viachristi.org

Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky 40504
Contact:
Site Public Contact
859-629-7169
ResearchInstituteInquiries@CommonSpirit.org

East Jefferson General Hospital
Metairie, Louisiana 70006
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie, Louisiana 70006
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

Maine Medical Center-Bramhall Campus
Portland, Maine 04102
Contact:
Site Public Contact
207-885-7565

Maine Medical Center- Scarborough Campus
Scarborough, Maine 04074
Contact:
Site Public Contact
207-396-8090
wrighd@mmc.org

Maine Medical Partners - South Portland
South Portland, Maine 04106
Contact:
Site Public Contact
207-396-8670
ClinicalResearch@mmc.org

Anne Arundel Medical Center
Annapolis, Maryland 21401
Contact:
Site Public Contact
443-481-1320
research@luminishealth.org

Maryland Proton Treatment Center
Baltimore, Maryland 21201
Contact:
Site Public Contact
410-369-5226
info@mdproton.com

University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland 21201
Contact:
Site Public Contact
800-888-8823

UM Upper Chesapeake Medical Center
Bel Air, Maryland 21014
Contact:
Site Public Contact
443-643-3010

University of Maryland Shore Medical Center at Easton
Easton, Maryland 21601
Contact:
Site Public Contact
410-822-1000
Christina.weisenborn@umm.edu

Beverly Hospital
Beverly, Massachusetts 01915
Contact:
Site Public Contact
978-922-3000

Lahey Hospital and Medical Center
Burlington, Massachusetts 01805
Contact:
Site Public Contact
781-744-3421
lhmc-cancer-clinical-trials@lahey.org

Addison Gilbert Hospital
Gloucester, Massachusetts 01930
Contact:
Site Public Contact
978-283-4000

Lahey Medical Center-Peabody
Peabody, Massachusetts 01960
Contact:
Site Public Contact
781-744-3421
lhmc-cancer-clinical-trials@lahey.org

Winchester Hospital
Winchester, Massachusetts 01890
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
Contact:
Site Public Contact
800-865-1125

McLaren Cancer Institute-Bay City
Bay City, Michigan 48706
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Saint Joseph Mercy Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Saint Joseph Mercy Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

McLaren Cancer Institute-Clarkston
Clarkston, Michigan 48346
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Michigan Healthcare Professionals Clarkston
Clarkston, Michigan 48346
Contact:
Site Public Contact
941-833-5700
rudi.ross@profoundresearch.io

Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Henry Ford Hospital
Detroit, Michigan 48202
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Michigan Healthcare Professionals Farmington
Farmington Hills, Michigan 48334
Contact:
Site Public Contact
941-833-5700
rudi.ross@profoundresearch.io

Weisberg Cancer Treatment Center
Farmington Hills, Michigan 48334
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

McLaren Cancer Institute-Flint
Flint, Michigan 48532
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Bronson Methodist Hospital
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Sparrow Hospital
Lansing, Michigan 48912
Contact:
Site Public Contact
517-364-9400

McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan 48446
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Michigan Healthcare Professionals Macomb
Macomb, Michigan 48044
Contact:
Site Public Contact
rudi.ross@profoundresearch.io

Michigan Healthcare Professionals Madison Heights
Madison Heights, Michigan 48071
Contact:
Site Public Contact
941-833-5700
rudi.ross@profoundresearch.io

McLaren Cancer Institute-Macomb
Mount Clemens, Michigan 48043
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

McLaren Cancer Institute-Northern Michigan
Petoskey, Michigan 49770
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Saint Joseph Mercy Oakland
Pontiac, Michigan 48341
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

McLaren-Port Huron
Port Huron, Michigan 48060
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

William Beaumont Hospital-Royal Oak
Royal Oak, Michigan 48073
Contact:
Site Public Contact
248-551-7695

Ascension Saint Mary's Hospital
Saginaw, Michigan 48601
Contact:
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Marie Yeager Cancer Center
Saint Joseph, Michigan 49085
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Ascension Saint Joseph Hospital
Tawas City, Michigan 48764
Contact:
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Munson Medical Center
Traverse City, Michigan 49684
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

William Beaumont Hospital - Troy
Troy, Michigan 48085
Contact:
Site Public Contact
248-551-7695

GenesisCare USA - Troy
Troy, Michigan 48098
Contact:
Site Public Contact
rudi.ross@profoundresearch.io

Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan 48322
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

University of Michigan Health - West
Wyoming, Michigan 49519
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Miller-Dwan Hospital
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Saint Luke's Hospital of Duluth
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-249-7825
kdean@slhduluth.com

Hennepin County Medical Center
Minneapolis, Minnesota 55415
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota 55416
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Regions Hospital
Saint Paul, Minnesota 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri 65212
Contact:
Site Public Contact
573-882-7440

Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

University of Kansas Cancer Center - North
Kansas City, Missouri 64154
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri 64064
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri 64116
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Delbert Day Cancer Institute at PCRMC
Rolla, Missouri 65401
Contact:
Site Public Contact
573-458-7504
research@phelpshealth.org

SSM Health Saint Louis University Hospital
Saint Louis, Missouri 63104
Contact:
Site Public Contact
314-977-4440

Washington University School of Medicine
Saint Louis, Missouri 63110
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center-South County
Saint Louis, Missouri 63129
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center at Christian Hospital
Saint Louis, Missouri 63136
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri 63376
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Mercy Hospital Springfield
Springfield, Missouri 65804
Contact:
Site Public Contact
417-269-4520

Billings Clinic Cancer Center
Billings, Montana 59101
Contact:
Site Public Contact
800-996-2663
research@billingsclinic.org

Saint James Community Hospital and Cancer Treatment Center
Butte, Montana 59701
Contact:
Site Public Contact
406-723-2621

Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
Contact:
Site Public Contact
402-559-5600

University of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire 03301
Contact:
Site Public Contact
603-224-2556

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire 03756
Contact:
Site Public Contact
800-639-6918
cancer.research.nurse@dartmouth.edu

Solinsky Center for Cancer Care
Manchester, New Hampshire 03103
Contact:
Site Public Contact
800-339-6484

Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey 07920
Contact:
Site Public Contact
212-639-7592

Cooper Hospital University Medical Center
Camden, New Jersey 08103
Contact:
Site Public Contact
856-325-6757

AtlantiCare Surgery Center
Egg Harbor Township, New Jersey 08234
Contact:
Site Public Contact
609-748-7200

Saint Barnabas Medical Center
Livingston, New Jersey 07039
Contact:
Site Public Contact
973-322-2934
joanne.loeb@rwjbh.org

Memorial Sloan Kettering Monmouth
Middletown, New Jersey 07748
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Bergen
Montvale, New Jersey 07645
Contact:
Site Public Contact
212-639-7592

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08903
Contact:
Site Public Contact
732-235-7356

Rutgers New Jersey Medical School
Newark, New Jersey 07101
Contact:
Site Public Contact
732-235-7356

The Valley Hospital-Luckow Pavilion
Paramus, New Jersey 07652
Contact:
Site Public Contact
201-634-5792

Sidney Kimmel Cancer Center Washington Township
Sewell, New Jersey 08080
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey 08876
Contact:
Site Public Contact
908-685-2481
Siby.Varughese@rwjbh.org

MD Anderson Cancer Center at Cooper-Voorhees
Voorhees, New Jersey 08043
Contact:
Site Public Contact
856-325-6757

University of New Mexico Cancer Center
Albuquerque, New Mexico 87102
Contact:
Site Public Contact
505-925-0348
HSC-ClinicalTrialInfo@salud.unm.edu

Presbyterian Kaseman Hospital
Albuquerque, New Mexico 87110
Contact:
Site Public Contact
505-559-6113
WBurman@phs.org

Presbyterian Rust Medical Center/Jorgensen Cancer Center
Rio Rancho, New Mexico 87124
Contact:
Site Public Contact
505-559-6113
WBurman@phs.org

Northwell Health Imbert Cancer Center
Bay Shore, New York 11706
Contact:
Site Public Contact
516-734-8896

New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York 11215
Contact:
Site Public Contact
718-780-3677
Adg9003@nyp.org

Roswell Park Cancer Institute
Buffalo, New York 14263
Contact:
Site Public Contact
800-767-9355
askroswell@roswellpark.org

Memorial Sloan Kettering Commack
Commack, New York 11725
Contact:
Site Public Contact
212-639-7592

Noyes Memorial Hospital/Myers Cancer Center
Dansville, New York 14437
Contact:
Site Public Contact
WCICTOresearch@urmc.rochester.edu

Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York 14905
Contact:
Site Public Contact
607-271-7000

The New York Hospital Medical Center of Queens
Flushing, New York 11355
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Glens Falls Hospital
Glens Falls, New York 12801
Contact:
Site Public Contact
518-926-6700

Memorial Sloan Kettering Westchester
Harrison, New York 10604
Contact:
Site Public Contact
212-639-7592

Northwell Health/Center for Advanced Medicine
Lake Success, New York 11042
Contact:
Site Public Contact
516-734-8896

Lenox Hill Hospital
New York, New York 10021
Contact:
Site Public Contact
516-734-8896

Manhattan Eye Ear and Throat Hospital
New York, New York 10065
Contact:
Site Public Contact
212-434-4460

Memorial Sloan Kettering Cancer Center
New York, New York 10065
Contact:
Site Public Contact
212-639-7592

Highland Hospital
Rochester, New York 14620
Contact:
Site Public Contact
585-341-8113

University of Rochester
Rochester, New York 14642
Contact:
Site Public Contact
585-275-5830

Phelps Memorial Hospital Center
Sleepy Hollow, New York 10591
Contact:
Site Public Contact
914-366-1600

Stony Brook University Medical Center
Stony Brook, New York 11794
Contact:
Site Public Contact
800-862-2215

State University of New York Upstate Medical University
Syracuse, New York 13210
Contact:
Site Public Contact
315-464-5476

Memorial Sloan Kettering Nassau
Uniondale, New York 11553
Contact:
Site Public Contact
212-639-7592

Westchester Medical Center
Valhalla, New York 10595
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Wilmot Cancer Institute at Webster
Webster, New York 14580
Contact:
Site Public Contact
WCICTOresearch@urmc.rochester.edu

Duke Cancer Institute Cary
Cary, North Carolina 27518
Contact:
Site Public Contact
919-781-7070

UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina 27599
Contact:
Site Public Contact
877-668-0683
cancerclinicaltrials@med.unc.edu

Durham VA Medical Center
Durham, North Carolina 27705
Contact:
Site Public Contact
919-286-0411
VHADURcancertrials@va.gov

Duke University Medical Center
Durham, North Carolina 27710
Contact:
Site Public Contact
888-275-3853

Duke Raleigh Hospital
Raleigh, North Carolina 27609
Contact:
Site Public Contact
919-862-5400

Novant Cancer Institute Radiation Oncology - Supply
Supply, North Carolina 28462
Contact:
Site Public Contact
910-754-4716

Novant Health Cancer Institute Radiation Oncology - Wilmington
Wilmington, North Carolina 28401
Contact:
Site Public Contact
910-251-1839

Novant Health New Hanover Regional Medical Center
Wilmington, North Carolina 28401
Contact:
Site Public Contact
910-342-3000

Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Broadway Medical Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Roger Maris Cancer Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

Altru Cancer Center
Grand Forks, North Dakota 58201
Contact:
Site Public Contact
701-780-6520

Summa Health System - Akron Campus
Akron, Ohio 44304
Contact:
Site Public Contact
330-375-4221
cancerresearch@summahealth.org

Cleveland Clinic Akron General
Akron, Ohio 44307
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

UH Seidman Cancer Center at UH Avon Health Center
Avon, Ohio 44011
Contact:
Site Public Contact
800-641-2422

Summa Health System - Barberton Campus
Barberton, Ohio 44203
Contact:
Site Public Contact
330-375-4221
cancerresearch@summahealth.org

UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio 44122
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio 45219
Contact:
Site Public Contact
513-584-7698
cancer@uchealth.com

Case Western Reserve University
Cleveland, Ohio 44106
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

Cleveland Clinic Foundation
Cleveland, Ohio 44195
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Contact:
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Cleveland Clinic Cancer Center Mansfield
Mansfield, Ohio 44906
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio 44124
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

Summa Health Medina Medical Center
Medina, Ohio 44256
Contact:
Site Public Contact
330-375-4221
cancerresearch@summahealth.org

UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio 44060
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio 44130
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

University Hospitals Parma Medical Center
Parma, Ohio 44129
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

University Hospitals Portage Medical Center
Ravenna, Ohio 44266
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

North Coast Cancer Care
Sandusky, Ohio 44870
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

UH Seidman Cancer Center at Firelands Regional Medical Center
Sandusky, Ohio 44870
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Cleveland Clinic Cancer Center Strongsville
Strongsville, Ohio 44136
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

ProMedica Flower Hospital
Sylvania, Ohio 43560
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

South Pointe Hospital
Warrensville Heights, Ohio 44122
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

University of Cincinnati Cancer Center-West Chester
West Chester, Ohio 45069
Contact:
Site Public Contact
513-584-7698
cancer@uchealth.com

Cleveland Clinic Wooster Family Health and Surgery Center
Wooster, Ohio 44691
Contact:
Site Public Contact
866-223-8100
TaussigResearch@ccf.org

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Legacy Mount Hood Medical Center
Gresham, Oregon 97030
Contact:
Site Public Contact
503-413-2150

Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon 97210
Contact:
Site Public Contact
800-220-4937
cancer@lhs.org

Providence Portland Medical Center
Portland, Oregon 97213
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Oregon Health and Science University
Portland, Oregon 97239
Contact:
Site Public Contact
503-494-1080
trials@ohsu.edu

Legacy Meridian Park Hospital
Tualatin, Oregon 97062
Contact:
Site Public Contact
503-413-1742

Saint Luke's Cancer Center - Allentown
Allentown, Pennsylvania 18104
Contact:
Site Public Contact
610-776-4714

UPMC Altoona
Altoona, Pennsylvania 16601
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania 15009
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania 18015
Contact:
Site Public Contact
484-503-4151

Crozer-Keystone Regional Cancer Center at Broomall
Broomall, Pennsylvania 19008
Contact:
Site Public Contact
610-284-8237
Jolene.garney@crozer.org

Carlisle Regional Cancer Center
Carlisle, Pennsylvania 17015
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania 19317
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Chambersburg Hospital
Chambersburg, Pennsylvania 17201
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Delaware County Memorial Hospital
Drexel Hill, Pennsylvania 19026
Contact:
Site Public Contact
610-284-8237
jolene.garney@crozer.org

Saint Luke's Hospital-Anderson Campus
Easton, Pennsylvania 18045
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Ephrata Cancer Center
Ephrata, Pennsylvania 17522
Contact:
Site Public Contact
717-721-4840

UPMC Hillman Cancer Center Erie
Erie, Pennsylvania 16505
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Saint Vincent Hospital
Erie, Pennsylvania 16544
Contact:
Site Public Contact
814-452-5000

UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania 16121
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Adams Cancer Center
Gettysburg, Pennsylvania 17325
Contact:
Site Public Contact
877-441-7957

Crozer Regional Cancer Center at Brinton Lake
Glen Mills, Pennsylvania 19342
Contact:
Site Public Contact
610-284-8237

UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania 15601
Contact:
Site Public Contact
724-838-1900

UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania 17109
Contact:
Site Public Contact
717-724-6765
klitchfield@PINNACLEHEALTH.org

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania 17033-0850
Contact:
Site Public Contact
717-531-3779
CTO@hmc.psu.edu

IRMC Cancer Center
Indiana, Pennsylvania 15701
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Jefferson Hospital
Jefferson Hills, Pennsylvania 15025
Contact:
Site Public Contact
412-359-3043
ddefazio@wpahs.org

UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania 15901
Contact:
Site Public Contact
814-534-4724

Sechler Family Cancer Center
Lebanon, Pennsylvania 17042
Contact:
Site Public Contact
717-741-8303
doxenberg@wellspan.org

Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania 17837
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

Yolanda G Barco Oncology Institute
Meadville, Pennsylvania 16335
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania 17050
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Forbes Hospital
Monroeville, Pennsylvania 15146
Contact:
Site Public Contact
412-858-7746

UPMC Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Hillman Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Hillman Cancer Center in Coraopolis
Moon, Pennsylvania 15108
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Allegheny Valley Hospital
Natrona Heights, Pennsylvania 15065
Contact:
Site Public Contact
Dawnmarie.DeFazio@ahn.org

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 19107
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Jefferson Torresdale Hospital
Philadelphia, Pennsylvania 19114
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
Contact:
Site Public Contact
877-284-2000

UPMC-Saint Margaret
Pittsburgh, Pennsylvania 15215
Contact:
Site Public Contact
412-784-4900

West Penn Hospital
Pittsburgh, Pennsylvania 15224
Contact:
Site Public Contact
412-578-5000

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-647-8073

UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-621-2334

UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
Contact:
Site Public Contact
412-367-6454

UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania 15243
Contact:
Site Public Contact
412-502-3920

Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania 17901
Contact:
Site Public Contact
800-275-6401
HemonCCTrials@geisinger.edu

Saint Luke's Hospital - Upper Bucks Campus
Quakertown, Pennsylvania 18951
Contact:
Site Public Contact
610-776-4714

Saint Luke's Hospital-Quakertown Campus
Quakertown, Pennsylvania 18951
Contact:
Site Public Contact
610-776-4714

UPMC Cancer Center at UPMC Northwest
Seneca, Pennsylvania 16346
Contact:
Site Public Contact
814-676-7900

Saint Luke's Hospital - Monroe Campus
Stroudsburg, Pennsylvania 18360
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Chester County Hospital
West Chester, Pennsylvania 19380
Contact:
Site Public Contact
610-431-5297

Reading Hospital
West Reading, Pennsylvania 19611
Contact:
Site Public Contact
610-988-9323

Wexford Health and Wellness Pavilion
Wexford, Pennsylvania 15090
Contact:
Site Public Contact
Dawnmarie.DeFazio@ahn.org

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Divine Providence Hospital
Williamsport, Pennsylvania 17754
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

WellSpan Health-York Cancer Center
York, Pennsylvania 17403
Contact:
Site Public Contact
877-441-7957

UPMC Memorial
York, Pennsylvania 17408
Contact:
Site Public Contact
717-724-6760

Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina 29910
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Medical University of South Carolina
Charleston, South Carolina 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Saint Francis Hospital
Greenville, South Carolina 29601
Contact:
Site Public Contact
864-603-6213
melissa_beckman@bshsi.org

Saint Francis Cancer Center
Greenville, South Carolina 29607
Contact:
Site Public Contact
864-603-6213
melissa_beckman@bshsi.org

Self Regional Healthcare
Greenwood, South Carolina 29646
Contact:
Site Public Contact
864-725-4771
nmcgaha@selfregional.org

Gibbs Cancer Center-Pelham
Greer, South Carolina 29651
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Spartanburg Medical Center
Spartanburg, South Carolina 29303
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
Contact:
Site Public Contact
800-811-8480

MD Anderson in The Woodlands
Conroe, Texas 77384
Contact:
Site Public Contact
866-632-6789
askmdanderson@mdanderson.org

UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
Contact:
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

Brooke Army Medical Center
Fort Sam Houston, Texas 78234
Contact:
Site Public Contact
210-916-4837

MD Anderson West Houston
Houston, Texas 77079
Contact:
Site Public Contact
877-632-6789
askmdanderson@mdanderson.org

MD Anderson League City
League City, Texas 77573
Contact:
Site Public Contact
877-632-6789
askmdanderson@mdanderson.org

UT Southwestern Clinical Center at Richardson/Plano
Richardson, Texas 75080
Contact:
Site Public Contact
972-669-7044
Suzanne.cole@utsouthwestern.edu

University of Texas Health Science Center at San Antonio
San Antonio, Texas 78229
Contact:
Site Public Contact
210-450-3800
phoresearchoffice@uthscsa.edu

MD Anderson in Sugar Land
Sugar Land, Texas 77478
Contact:
Site Public Contact
877-632-6789
askmdanderson@mdanderson.org

Sandra L Maxwell Cancer Center
Cedar City, Utah 84720
Contact:
Site Public Contact
435-868-5680
officeofresearch@imail.org

Farmington Health Center
Farmington, Utah 84025
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Intermountain Medical Center
Murray, Utah 84107
Contact:
Site Public Contact
801-507-3950
officeofresearch@imail.org

McKay-Dee Hospital Center
Ogden, Utah 84403
Contact:
Site Public Contact
801-387-7426
officeofresearch@imail.org

Utah Valley Regional Medical Center
Provo, Utah 84604
Contact:
Site Public Contact
801-357-7965
officeofresearch@imail.org

Saint George Regional Medical Center
Saint George, Utah 84770
Contact:
Site Public Contact
833-321-3332
officeofresearch@imail.org

University of Utah Sugarhouse Health Center
Salt Lake City, Utah 84106
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Central Vermont Medical Center/National Life Cancer Treatment
Berlin, Vermont 05602
Contact:
Site Public Contact
802-225-5400

University of Vermont Medical Center
Burlington, Vermont 05401
Contact:
Site Public Contact
802-656-4101
rpo@uvm.edu

Norris Cotton Cancer Center-North
Saint Johnsbury, Vermont 05819
Contact:
Site Public Contact
800-639-6918
cancer.research.nurse@hitchcock.org

Bon Secours Saint Francis Medical Center
Midlothian, Virginia 23114
Contact:
Site Public Contact
804-893-8978
anne_carmellat@bshsi.org

Bon Secours Cancer Institute at Reynolds Crossing
Richmond, Virginia 23230
Contact:
Site Public Contact
804-893-8978
Anne_caramella@bshsi.org

Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia 23298
Contact:
Site Public Contact
CTOclinops@vcu.edu

Virginia Mason Medical Center
Seattle, Washington 98101
Contact:
Site Public Contact
206-287-6275
cancerresearch@virginiamason.org

Legacy Cancer Institute Medical Oncology and Day Treatment
Vancouver, Washington 98684
Contact:
Site Public Contact
oncologyresearch@lhs.org

Legacy Salmon Creek Hospital
Vancouver, Washington 98686
Contact:
Site Public Contact
503-413-2150

Langlade Hospital and Cancer Center
Antigo, Wisconsin 54409
Contact:
Site Public Contact
715-623-9869
Juli.Alford@aspirus.org

ThedaCare Regional Cancer Center
Appleton, Wisconsin 54911
Contact:
Site Public Contact
920-364-3604
ResearchDept@thedacare.org

Ascension Saint Elizabeth Hospital
Appleton, Wisconsin 54915
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Northwest Wisconsin Cancer Center
Ashland, Wisconsin 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin 53045
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Calumet Hospital
Chilton, Wisconsin 53014
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin 54701
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Ascension Saint Francis - Reiman Cancer Center
Franklin, Wisconsin 53132
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Bellin Memorial Hospital
Green Bay, Wisconsin 54301
Contact:
Site Public Contact
920-435-8326

Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin 54301
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin 54303
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin 53038
Contact:
Site Public Contact
920-699-3500
lynda.persico@uwmf.wisc.edu

Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

University of Wisconsin Carbone Cancer Center
Madison, Wisconsin 53792
Contact:
Site Public Contact
800-622-8922

Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin 53051
Contact:
Site Public Contact
262-257-5100

Ascension Columbia Saint Mary's Hospital Ozaukee
Mequon, Wisconsin 53097
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Columbia Saint Mary's Hospital - Milwaukee
Milwaukee, Wisconsin 53211
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Site Public Contact
414-805-3666

Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Zablocki Veterans Administration Medical Center
Milwaukee, Wisconsin 53295
Contact:
Site Public Contact
888-469-6614

Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin 54548
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

ProHealth D N Greenwald Center
Mukwonago, Wisconsin 53149
Contact:
Site Public Contact
research.institute@phci.org

Drexel Town Square Health Center
Oak Creek, Wisconsin 53154
Contact:
Site Public Contact
414-805-0505

ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin 53066
Contact:
Site Public Contact
262-928-7878

Ascension Mercy Hospital
Oshkosh, Wisconsin 54904
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension All Saints Hospital
Racine, Wisconsin 53405
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Racine
Racine, Wisconsin 53406
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Saint Mary's Hospital
Rhinelander, Wisconsin 54501
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin 54868
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Saint Vincent Hospital Cancer Center at Sheboygan
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Saint Michael's Hospital
Stevens Point, Wisconsin 54481
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin 54482
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin 54235-1495
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Aurora Medical Center in Summit
Summit, Wisconsin 53066
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin 54241
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

UW Cancer Center at ProHealth Care
Waukesha, Wisconsin 53188
Contact:
Site Public Contact
262-928-5539
Chanda.miller@phci.org

Aspirus Regional Cancer Center
Wausau, Wisconsin 54401
Contact:
Site Public Contact
877-405-6866

Ascension Medical Group Southeast Wisconsin - Mayfair Road
Wauwatosa, Wisconsin 53226
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora West Allis Medical Center
West Allis, Wisconsin 53227
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, Wisconsin 53095
Contact:
Site Public Contact
414-805-0505

Marshfield Medical Center - Weston
Weston, Wisconsin 54476
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin 54494
Contact:
Site Public Contact
715-422-7718

More Details

NCT ID
NCT05050084
Status
Recruiting
Sponsor
NRG Oncology

Detailed Description

PRIMARY OBJECTIVES: I. To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with radiation therapy (RT) alone instead of 6 months androgen deprivation therapy (ADT) + RT experience non-inferior rate of distant metastasis. (De-intensification study) II. To determine whether men with NCCN UIR prostate cancer who are in the higher genomic risk (Decipher score >= 0.40) will have a superior metastasis-free survival through treatment intensification with darolutamide added to the standard of RT plus 6 months ADT. (Intensification study) SECONDARY OBJECTIVES: I. To compare overall survival (OS) between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. II. To compare time to prostate specific antigen (PSA) failure between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. III. To compare metastasis free survival (MFS) based on conventional imaging between the standard of care (RT plus 6 months of ADT) and de-intensification intervention (RT alone). IV. To compare MFS based on either conventional and/or molecular imaging between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. V. To compare cumulative incidence of locoregional failure based upon conventional imaging and/ or biopsy between standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months ADT plus darolutamide) interventions. VI. To compare cumulative incidence of distant metastasis based upon conventional imaging between standard of care (RT plus 6 months of ADT) and intensification intervention (RT plus 6 months ADT plus darolutamide). VII. To compare cumulative incidence of distant metastasis based upon either conventional and/or molecular imaging between standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. VIII. To compare prostate cancer-specific mortality between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. IX. To compare sexual and hormonal related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. X. To compare fatigue, as measured by the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue instrument, between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. XI. To compare cognition, as measured by the Functional Assessment of Chronic Illness Therapy-Cognitive (FACT-Cog) perceived cognitive abilities subscale, between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. EXPLORATORY OBJECTIVES: I. To compare changes in cardio-metabolic markers, including body mass index, lipids, blood glucose, complete blood count (CBC), comprehensive metabolic panel (CMP), and hemoglobin (Hgb) A1c, between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. II. To compare PSA failure-free survival with non-castrate testosterone and no additional therapies between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. III. To compare cumulative incidence of locoregional failure based upon either conventional and/or molecular imaging between standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. IV. To compare castrate-resistant prostate cancer (CRPC) between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. V. To compare bowel and urinary function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. VI. To compare time to testosterone recovery (defined as a T > 200ng/dL) between the standard of care (RT plus 6 months of ADT) and intensification (RT plus 6 months of ADT plus darolutamide) interventions. VII. To compare health utilities, as measured by the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L), between the standard of care (RT plus 6 months of ADT) and either the de-intensification (RT alone) or intensification (RT plus 6 months of ADT plus darolutamide) interventions. VIII. To develop and assess a machine learning/artificial intelligence algorithm for radiotherapy planning and/or quality assurance. IX. To perform future translational correlative studies using biological data, Decipher results, and clinical outcomes. OUTLINE: DE-INTENSIFICATION STUDY: Patients with Decipher score < 0.40 are randomized to 1 of 2 arms. ARM I: Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo RT as Arm I. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days. INTENSIFICATION STUDY: Patients with Decipher score >= 0.40 are randomized to 1 of 2 arms. ARM III: Patients receive treatment as in Arm II. ARM IV: Patients receive RT and ADT as in Arm II. Patients also receive darolutamide orally (PO) twice daily (BID). Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 3, 6, 12, 24, 36, 48 and 60 months.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.